Study of the Efficacy of Daylight Activated Photodynamic Therapy in

Status Enrolling by invitation

Clinical Trial Summary

The aim of the project is to determine whether daylight activated photodynamic therapy is effective in treating cutaneous leishmaniasis caused by L. major and L. tropical.

PDT is classically performed as a two-step procedure in which MAL application to the lesion constitutes the first step, and PpIX activation by light of appropriate wavelength from an artificial light source constitutes the second step. Based on the knowledge that red and blue light required to activate PpIX are part of the daylight spectrum, the investigators postulated that effective PpIX activation can be obtained by exposure of the MAL treated lesions to daylight thus substantially simplifying the PDT procedure by omitting the 3 hour incubation period and the subsequent exposure to artificial light. In accord, in a recent study the investigators showed that daylight-activated PDT (DA-PDT) was as effective as conventional MAL-PDT in treating precancerous actinic keratoses lesion. Furthermore the investigators found that DA-PDT is significantly less painful than conventional MAL-PDT.

The investigators now propose to study the efficacy of DA-PDT in the treatment of cutaneous leishmaniasis. DA-PDT has obvious advantages to conventional leishmania treatment forms:

As opposed to most of the available treatment options, DA-PDT is a self-administered procedure that does not require the assistance of medical personnel. Secondly, judged by our experience with MAL-PDT, only few treatment sessions are required for effective parasite killing as opposed to the prolonged procedures usually required for treatment of leishmaniasis. Third, PDT has the far the best safety profile of all available treatment options.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00840359
Study type	Interventional
Source	Hadassah Medical Organization
Contact
Status	Enrolling by invitation
Phase	Phase 2
Start date	September 2009
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01988909` - WR 279,396 for the Treatment of Cutaneous Leishmaniasis	Phase 2
Enrolling by invitation	`NCT00737386` - Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank	N/A
Completed	`NCT00233545` - Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia	Phase 2
Completed	`NCT01462500` - Pharmacokinetics of Miltefosine in Children and Adults	Phase 4
Completed	`NCT01011309` - A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis	Phase 2
Completed	`NCT01301924` - Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis	Phase 2/Phase 3
Not yet recruiting	`NCT02281669` - Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients	N/A
Completed	`NCT01464242` - Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis	Phase 2/Phase 3
Completed	`NCT01790659` - Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama	Phase 3
Completed	`NCT01050907` - Miltefosine to Treat Mucocutaneous Leishmaniasis	Phase 2
Completed	`NCT04340128` - Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)	Phase 3
Terminated	`NCT00317629` - Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis	Phase 3
Completed	`NCT00351520` - Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica	Phase 3
Completed	`NCT01381055` - Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis	Phase 2/Phase 3
Completed	`NCT01050777` - Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis	Phase 0
Completed	`NCT01380314` - Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis	Phase 2
Terminated	`NCT01380301` - Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony	Phase 2
Completed	`NCT00703924` - Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World	Phase 2
Completed	`NCT00344084` - Surveillance for Leishmaniasis Skin Lesions in Mali
Completed	`NCT03023111` - Miltefosine and GM-CSF in Cutaneous Leishmaniasis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms